Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 12/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 6/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 6/20 | 1.00 |
| ▸ | PRKDC | P78527 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 0.58 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21099894 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL23896256 | 0.92 | PIK3CA (0.85) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL25735869 | 0.92 | PIK3CA (0.85) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL23896257 | 0.92 | PIK3CA (0.85) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL23895633 | 0.90 | PIK3CA (0.81) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL23896129 | 0.89 | PIK3CA (0.80) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL25179016 | 0.89 | PIK3CB (0.80) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL30081718 | 0.89 | PIK3CB (0.80) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL23895845 | 0.89 | PIK3CB (0.80) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL23896128 | 0.89 | PIK3CA (0.80) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264581-A1 | P110 INHIBITORS FOR THE TREATMENT OF CANCER | LEAPFROG BIO, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| US-20240294876-A1 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIV SOUTHERN CALIFORNIA (US) | 2024-09-05 | — | — | US | claimed |
| EP-4341386-A2 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | University of Southern California (US) | 2024-03-27 | — | — | EP | claimed |
| CN-117751182-A | Method for amplifying human granulocyte-macrophage progenitor cells and application thereof | 南加利福尼亚大学 | 2024-03-22 | — | — | CN | claimed |
| WO-2022245977-A2 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-11-24 | — | — | WO | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025264581-A1 | P110 INHIBITORS FOR THE TREATMENT OF CANCER | LEAPFROG BIO, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | disclosed |
| US-20250277062-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2025-09-04 | — | — | US | disclosed |
| US-12404348-B2 | Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2023092094-A2 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230111917-A1 | KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2022246112-A1 | CHIMERIC ANTIGEN RECEPTOR-MODIFIED GRANULOCYTE-MACROPHAGE PROGENITORS FOR CANCER IMMUNOTHERAPY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-11-24 | — | — | WO | disclosed |
| WO-2022245977-A2 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-11-24 | — | — | WO | disclosed |
| WO-2022225728-A9 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022225728-A2 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| US-20220332717-A1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230111917-A1 | KINASE ANTAGONISTS | MTOR, RPS6KA3, AKT3 | PIK3CA 4/4885PIK3CB 21/4885PIK3CD 12/4885 |
| US-20250277062-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | PIK3CA 377/4885PIK3CB 256/4885PIK3CD 619/4885 |
| US-12404348-B2 | Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof | ERBB2, ACP1, TK1 | PIK3CA 377/4885PIK3CB 256/4885PIK3CD 619/4885 |
| US-20220332717-A1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3CA, PIK3CD, PIK3C2B | PIK3CA 1/4885PIK3CB 4/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.